Get the Stockscreener App
51.98
1.35%
-0.71
Pre-market:
52.10
0.12
+0.23%
Pulse Biosciences Inc stock is traded at $51.98, with a volume of 550.58K.
It is down -1.35% in the last 24 hours and up +3.09% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
See More
Previous Close:
$52.69
Open:
$53.75
24h Volume:
550.58K
Relative Volume:
1.14
Market Cap:
$3.71B
Revenue:
$751.00K
Net Income/Loss:
$-74.57M
P/E Ratio:
-47.12
EPS:
-1.1031
Net Cash Flow:
$-55.52M
1W Performance:
+4.78%
1M Performance:
+3.09%
6M Performance:
+148.35%
1Y Performance:
+193.67%
1-Day Range:
$51.87
$56.74
1-Week Range:
$49.01
$56.74
52-Week Range:
$12.56
$58.90
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, RMD, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
51.98 | 3.71B | 751.00K | -74.57M | -55.52M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
398.30 | 140.71B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
182.52 | 49.72B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
222.30 | 32.07B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
65.39 | 31.61B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.30 | 30.09B | 29.14B | 1.07B | 1.05B | 1.1956 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Mizuho | Outperform |
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Pulse Biosciences stock reports 100 patient trial milestone - AD HOC NEWS
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday - Benzinga
BTIG initiates Pulse Biosciences stock coverage with buy rating - Investing.com India
BTIG Initiates Pulse Biosciences at Buy With $70 Price Target - Yahoo Finance
BTIG initiates coverage of Pulse Biosciences with Buy rating, $70 price target - TradingView
BTIG initiates Pulse Biosciences stock coverage with buy rating By Investing.com - Investing.com Canada
Is Pulse Biosciences (PLSE) Fully Valued As Its Thyroid Trial Reaches 100 Patients? - simplywall.st
Pulse Biosciences, Inc (PLSE) Stock Analysis: A Healthcare Innovator with Strong Buy Ratings Amidst Volatile Market Conditions - DirectorsTalk Interviews
Pulse Biosciences Launches New ATM Equity Program - The Globe and Mail
Pulse Biosciences (NASDAQ: PLSE) Launches $85M ATM Offering at $54.21 Per Share - kalkinemedia.com
Form 8K Pulse Biosciences Inc For: 15 September By Investing.com - Investing.com Australia
Pulse Biosciences Opens New $85 Million At-the-Market Stock Offering - Minichart
Pulse Biosciences enters $85 million equity distribution agreement with Mizuho - Investing.com
Pulse Biosciences completes enrollment in thyroid nodule study By Investing.com - Investing.com Nigeria
Pulse Biosciences Finalizes Enrollment for PRECISE-BTN Trial Evaluating nPulse Vybrance System - kalkinemedia.com
Pulse Biosciences Completes Enrollment In The PRECISE-BTN Clinical Study Evaluating The nPulse Vybrance Percutaneous Electrode System For Symptomatic Benign Thyroid Nodules - marketscreener.com
Pulse Biosciences (PLSE) Advances PRECISE-BTN Trial as Valuation Reflects High Growth Expectations - GuruFocus
Pulse Biosciences completes enrollment in thyroid nodule study - Investing.com
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules - Business Wire
Why is Pulse Biosciences stock surging today? By Investing.com - Investing.com Nigeria
Pulse Biosciences stock hits all-time high at 56.15 USD By Investing.com - Investing.com Nigeria
Freedom Capital initiates Pulse Biosciences stock with buy rating By Investing.com - Investing.com Australia
Why Pulse Biosciences Stock Popped Today - theglobeandmail.com
Freedom Capital Markets Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $73 - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Pulse Biosciences stock hits all-time high at 56.15 USD - investing.com
$Pulse Biosciences (PLSE.US)$ the squeeze is onnnnnnnn - Moomoo
PLSE Initiates Coverage by Freedom Capital Markets -- Price Targ - GuruFocus
Freedom Capital initiates Pulse Biosciences stock with buy rating - investing.com
PLSE Q2 2026 Earnings: Narrower-Than-Expected Loss Yields 1.96% Surprise But Shares DeclineEPS Miss Report - careplusvn.com
(PLSE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Pulse Biosciences Stock Price Forecast. Should You Buy PLSE? - StockInvest.us
Pulse Biosciences stock holds steady as investors eye recent clinical and financial progress - AD HOC NEWS
Pulse Biosciences (PLSE) Grants Equity Awards to New Hires Amid High Price-to-Sales Valuation - GuruFocus
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Pulse Biosciences Inc (DE) (PLSE) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock By Investing.com - Investing.com Australia
Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock - Investing.com India
COO pays nearly $50 a share for Pulse Biosciences (NASDAQ: PLSE) - Stock Titan
Pulse Biosciences Inc (DE) (PLSE) Peer Comparison – Compare with Others - Value Research
$Pulse Biosciences (PLSE.US)$ New ATH 🔥 - Moomoo
Pulse Biosciences Reports Teplitsky Liane Rae as New Insider COO - Kalkine Media
Pulse Biosciences stock hits new high as insider buying fuels rally - AD HOC NEWS
Pulse Biosciences stock hits all-time high at 51.0 USD - Investing.com
Pulse Biosciences stock hits all-time high at 51.0 USD By Investing.com - Investing.com Canada
Pulse Biosciences (PLSE) Slips 2% as Shares Approach Key Support at $45.19IV Crush Alert - vinanet.vn
Pulse Biosciences Inc (DE) (PLSE) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Pulse Biosciences COO Liane Teplitsky buys $99,965 in stock By Investing.com - Investing.com Nigeria
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.34%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):